Bone growth occurs through the proliferation of specialized cells of the cartilage tissue, known as chondrocytes, on either end of a bone. This process requires the synthesis of extracellular matrix ...

Researchers have found that phosphodiesterase 3 (PDE3) inhibitors have the ability to boost long bone growth. Conventionally used to treat heart disease, thrombosis, and asthma, PDE3 inhibitors can ...

Company founded by Frazier Life Sciences, which led the Series A financing with participation from OrbiMed, Life Sciences at Goldman Sachs Alternatives, SR One, Longitude Capital and Enavate Sciences ...

Verona Pharma plc has announced the upcoming presentation of ten posters at the American Thoracic Society Conference 2025, highlighting analyses from its Phase 3 ENHANCE studies of Ohtuvayre ...

The FDA approved inhaled ensifentrine (Ohtuvayre) as maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, drugmaker Verona Pharma announced on Wednesday. A first-in-class ...

Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 Ensifentrine is a novel selective dual ...

Suzhou Junjian Yifang Biopharmaceutical Co. Ltd. has described pyrimido [6,1-a]isoquinolin-4-one derivatives acting as dual phosphodiesterase PDE3 and PDE4 inhibitors reported to be useful for the ...

AirNexis Therapeutics, a clinical stage biotech company developing therapeutics for pulmonary diseases, today announced the close of a $200 million Series A financing round and the in-license of a ...